Screening Tests

Screening Tests

Excluding ultrasound (which is also a type of screening test), there are two common screening tests for the most chromosome abnormalities (trisomy 21 and trisomy 18) available to women in pregnancy.

The first is the most widely undertaken (and by law must be offered to all women in the state of California) is the California Prenatal Screening Program.  This test consists several pieces that include a first trimester blood test measuring two biochemical analytes, a first trimester ultrasound to measure the nuchal translucency (NT) and a second trimester blood test measuring 4 biochemical analytes.  Although all three components of the test are not required – each portion adds to the accuracy of the test and is therefore recommended.

As an example, if only the NT portion of the exam was performed, data has shown that an NT exam alone will detect about 60% of chromosome abnormalities.  If the NT exam is omitted and someone elects to only undergo the second trimester blood test – the test will detect (result will be read out as “screen positive”) approximately 80% of the pregnancies affected with trisomy 21 and 67% of pregnancies affected with trisomy 18).  If only the two blood tests (one in the first trimester and one in the second trimester) are undertaken and the NT is omitted, the detection rate for trisomy 21 increases to approximately 85% and trisomy 18 to 79%.   If all three components are completed (first and second blood tests plus the NT ultrasound) the detection rate for trisomy 21 increases to 90% and for trisomy 18 to 81%.   For a more detailed explanation of the California Prenatal Screening Program a brochure can be found at:

In addition to screening for chromosome abnormalities, two other conditions undergo screening from the blood test in the second trimester of the California Prenatal Screening Program – neural tube defects (spina bifida) and a very rare condition called Smith-Lemli-Opitz syndrome and are formally reported if found to be positive.

The second relatively common screening test that has garnered patient favor in recent years is non-invasive prenatal testing (NIPT).  This type of screening test is marketed by several labs including Sequenom’s MaterniT 21, Ariosa’s Harmnony Prental Test, Genesis’ Serenity Prenatal Test, Natera’s Panorama Prenatal Screen, and Labcorp’s InformaSeq Prenatal Test.  While the molecular methodology for each test varies slightly – the basis for each of these tests is the same.  As a pregnancy develops, cells from the developing placenta (which is fetal in origin and therefore representative of the fetal genetic makup) undergo a process called apoptosis (cell turnover) that results in some of the content of those placental cells, including fragments of the nuclear DNA, being released into the maternal circulation.  This DNA – called “cell-free DNA” can then be quantified from a maternal blood sample.  Unfortunately, because it is fragmented and diluted in a sea of maternal DNA, there is an error rate associated with interpreting the result therefore the test is a screening test and not a diagnostic test.

 The Perinatologist’s perspective on the two screening tests.

There are advantages and disadvantages of each screening test – and to make things more confusing – those advantages and disadvantages are different depending on the age of the expecting mom.  For purposes of my narrative, I will exclude the cost of each test since each person’s insurance, deductible and maximum out of pocket expense are different.

The obvious advantage is the non-invasive nature of both tests.  In the case of the PNS, there are two blood tests and an ultrasound, while the NIPT relies on a single blood test. For many women, an invasive procedure such as an amniocentesis or CVS is frightening and anxiety provoking – while a blood test is relatively routine.

In addition to the non-invasive advantage there are two other significant advantages of the California PNS.  First is it’s nonspecific nature.  Although the test reports that it only screens for two chromosome abnormalities (trisomy 21 and trisomy 18), it is based on biochemistry (six biochemical analytes are measured in two different trimesters) and has the ability to pick up a biochemical abnormality in a pregnancy affected with a chromosome abnormality other than trisomy 21 and 18 (although the test result will indicate an increased risk for one of these two abnormalities).  This fact is what makes the California Prenatal Screening test a statistically better screening test for younger women who are at greater risk for chromosome abnormalities other than trisomy 21 and trisomy 18 compared to older women.  NIPT on the other hand has the advantage of being more specific for detecting the chromosome abnormalities seen in the older population (the trisomies).  Ultimately, for someone trying to get the advantage of both screening tests – both can be done – and that may be the right decision for someone averse to an invasive procedure looking for as much reassurance as possible.

Even though the NT is a formal part of the California Prenatal Screening Program, there are two reasons it should be performed on all women, even those undergoing NIPT or those choosing not to undergo any type of serum screening.  First, it accurately dates or confirms the due date of the pregnancy to within 3-5 days.  This becomes critical later in pregnancy when assigned gestational age affects decisions made by your care provider.  If the assigned due date is off by say 10 days…your pregnancy may be delivered 10 days too early … 10 days too late.  Alternatively, your pregnancy may be treated as a growth restricted pregnancy (as a result of incorrect dating) when really it is not.   The second, and probably the most compelling reason for undergoing a nuchal translucency is peace of mind.  In addition to visualizing the nuchal translucency, a tremendous amount of fetal anatomy can be seen at the exam and if a problem exists, it can be discussed.  While difficult, this discussion is better at 12 weeks rather than 20 weeks at the detailed anatomic survey ultrasound.

The main strength of NIPT is its detection rate for trisomy 21 (Down syndrome) with every company providing this test reporting a greater than 98% detection rate.  The main disadvantage of this test (and it isn’t really a fault of the test) is patient’s understanding of what the test tells them.  It seems more common than not that once a patient received a reassuring result from an NIPT – they assume everything is perfect.  The reality is NIPT has screened for the correct number of several chromosomes and left 19 other chromosomes uninterrogated.  Furthermore, with screening tests we are only talking about chromosome abnormalities and not genetic conditions.  Please read diagnostic testing to understand the differences between testing for chromosomes numbers and genetic conditions/syndromes/deletions/duplications.






A Perinatologist’s Perspective:

Screening tests are a cost effective method of identifying a pregnancy at risk for a chromosome abnormality.  It does not conclusively identify a pregnancy as “affected” or “not affected”, rather identifies those pregnancies “at high risk” or “at low risk” (and assigns a numeric value to that assessment).  If you are comfortable with a risk assessment – a screening test may be the right decision for you.  If you need to know definitively – a diagnostic test is probably the right choice.